ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Esperion Therapeutics (ESPR) Posts Wider Q1 Loss
May 4, 2021 4:38 PM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($3.50), $0.98 worse than the analyst estimate of ($2.52). Revenue for the quarter came in at $8 million versus the consensus estimate of $22.03 million.
As of March 31, 2021, cash, cash equivalents and investment securities available-for-sale totaled $217.9 million compared with $305.0 million at December 31, 2020. This amount does not include the $30 million upfront payment resulting from the expanded... More
